Neuralstem Inc (CUR) 0.32 $CUR Neuralstem Achie
Post# of 273254
Posted On: 09/24/2016 3:01:52 AM
Neuralstem Inc (CUR) 0.32 $CUR
Neuralstem Achieves 50% Enrollment in NSI-189 Phase 2 Trial in Major Depressive Disorder
GlobeNewswire - Wed Sep 21, 7:32AM CDT
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced that it has reached over 50% enrollment in its Phase 2 clinical trial evaluating NSI-189, a novel neurogenic small molecule, for the treatment of major depressive disorder (MDD).
CUR: 0.32 (+0.01)
Neuralstem Presented NSI-189 Preclinical Data in Type 1 and Type 2 Diabetes at the Annual Meeting of the Diabetic Neuropathy Study Group
GlobeNewswire - Mon Sep 12, 7:32AM CDT
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell proprietary technology, announced that Karl Johe, Ph.D., Chief Scientific Officer, presented the poster, "Therapeutic Efficacy of NSI-189 in Diabetic Mice," at the Annual Meeting of the Diabetic Neuropathy Study Group of the EASD (European Association for the Study of Diabetes), held in Bucharest, Romania, on September 11. The data demonstrate the potential for NSI-189 to reverse neuropathies resulting from diabetes in two well-recognized animal models.
CUR: 0.32 (+0.01)
Neuralstem Receives $20,000,000 Strategic Investment from Tianjin Pharmaceutical Group
GlobeNewswire - Mon Sep 12, 7:03AM CDT
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced that on September 7, 2016, it entered into definitive agreements with Tianjin Pharmaceutical Holding Group for the private placement of common stock and convertible preferred stock for gross proceeds of $20,000,000. Neuralstem intends to use the net proceeds from the offering for clinical research and development and general corporate purposes.
CUR: 0.32 (+0.01)
Neuralstem Reports Second Quarter 2016 Results and Provides Business and Clinical Updates
GlobeNewswire - Thu Aug 11, 3:05PM CDT
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, reported its financial results and provided business and clinical updates for the three and six months periods ended June 30, 2016.
CUR: 0.32 (+0.01)
Neuralstem Announces New Chairman and Further Reorganization Plans
GlobeNewswire - Mon Jun 13, 7:45AM CDT
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced, in furtherance of its reorganization plans and focus on clinical development, that Richard Daly, the company's president and chief executive officer, has been appointed chairman of the board of directors. Mr. Daly's appointment as chairman will allow Dr. Karl Johe, the company's founder, chief scientific officer and former chairman, to focus exclusively on the development of the company's product candidates.
CUR: 0.32 (+0.01)
Neuralstem Announces Plan of Reorganization to Further Align Business with Strategic Intent
PR Newswire - Fri May 20, 7:32AM CDT
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced a corporate reorganization to further align the company's resources on advancing the NSI-189 neurogenic small molecule program, currently in a Phase 2 clinical trial for the treatment of major depressive disorder, and to continue to pursue collaborations for the NSI-566 stem cell therapy program that will expedite clinical development.
CUR: 0.32 (+0.01)
Neuralstem to Raise $1.08 Million
PR Newswire - Thu May 12, 3:54PM CDT
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced that it has entered into a definitive agreement to sell 2,700,000 shares of its common stock and warrants to purchase 2,700,000 shares of common stock in a private placement. The securities are being sold in a private offering at a price of $0.40 per one share of common stock and one common stock purchase warrant. The warrants have an exercise price of $0.40 per share, are immediately exercisable and expire on the fifth anniversary of the date of issuance. The shares of common stock and warrants are immediately separable and will be issued separately.
CUR: 0.32 (+0.01)
Neuralstem Announces First Patient Enrolled in Phase 2 Clinical Trial in Major Depressive Disorder
PR Newswire - Thu May 12, 8:07AM CDT
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced that the first patient has been enrolled in the double-blind, placebo-controlled multi-center Phase 2 study of NSI-189 for the treatment of major depressive disorder (MDD).
CUR: 0.32 (+0.01)
Neuralstem Reports Fiscal First Quarter 2016 Results and Business Update
PR Newswire - Mon May 09, 7:05AM CDT
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, reported its financial results for the three months ended March 31, 2016 and provided a business update.
CUR: 0.32 (+0.01)
Neuralstem Prices Underwritten Public Offering of Securities
PR Newswire - Tue May 03, 7:22AM CDT
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $0.40 per share and warrants to purchase 20,000,000 shares of common stock. The warrants have an exercise price of $0.40 per share, are immediately exercisable and expire on the fifth anniversary of the date of issuance. The shares of common stock and warrants are immediately separable and will be issued separately.
CUR: 0.32 (+0.01)
Neuralstem Announces Proposed Public Offering of Securities
PR Newswire - Mon May 02, 3:01PM CDT
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The shares of common stock and warrants will be immediately separable and will be issued separately. All securities in the offering are being offered by Neuralstem. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Roth Capital Partners is acting as sole book runner and Brean Capital is acting as co-manager in the offering.
CUR: 0.32 (+0.01)
Diabetic Neuropathy Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/hz8k3l/diabetic) has announced the addition of the "Diabetic Neuropathy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Diabetic Neuropathy Overview - Therapeutics Development - Pipeline Products for Diabetic Neuropathy - Overview - Pipeline Products for Diabetic Neuropathy - Comparative Analysis - Diabetic Neuropathy - Therapeutics under Development by Companies - Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes - Diabetic Neuropathy - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Diabetic Neuropathy - Products under Development by Companies - Diabetic Neuropathy - Products under Investigation by Universities/Institutes - Diabetic Neuropathy - Companies Involved in Therapeutics Development - Araim Pharmaceuticals Inc. - Bristol-Myers Squibb Company - Cebix Incorporated - Celgene Corporation - Glucox Biotech AB - Longevity Biotech, Inc - Lpath, Inc. - Neuralstem, Inc. - NovaLead Pharma Pvt. Ltd. - Nuvo Research Inc. - Omeros Corporation - Pfizer Inc. - R-Tech Ueno, Ltd. - Reata Pharmaceuticals, Inc. - Relief Therapeutics S.A. - Sumitomo Dainippon Pharma Co., Ltd. - Virobay Inc. - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/hz8k3l/diabetic
PFE: 34.26 (+0.11), VBAY: (), BMY: 56.48 (+0.06), LPTN: 3.89 (+0.29), OMER: 11.64 (-0.26), CUR: 0.32 (+0.01), CELGZ: 1.24 (+0.04)
Neuralstem Presented Cell Therapy Update At Phacilitate Cell & Gene Therapy World Conference
PR Newswire - Wed Jan 27, 8:02AM CST
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company using neural stem cell technology to develop regenerative therapies and small molecule pharmaceutical drugs for CNS diseases and disorders, announced that Karl Johe, Ph.D., Neuralstem's Chairman and Chief Scientific Officer, provided an update on the company's ongoing NSI-566 cell therapy clinical programs at the Phacilitate Cell & Gene Therapy World conference in Washington D.C.
CUR: 0.32 (+0.01)
Global Ageing Development Pipeline Review, H2 2015
M2 - Wed Jan 27, 4:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/3tlrh3/ageing_pipeline) has announced the addition of the "Ageing - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ageing, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ageing and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Ageing Overview - Therapeutics Development - Pipeline Products for Ageing - Overview - Pipeline Products for Ageing - Comparative Analysis - Ageing - Therapeutics under Development by Companies - Ageing - Therapeutics under Investigation by Universities/Institutes - Ageing - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Ageing - Products under Development by Companies - Ageing - Products under Investigation by Universities/Institutes - Ageing - Companies Involved in Therapeutics Development - Bioo Therapeutics - Mapreg S.A.S. - Neuralstem, Inc. - RepliCel Life Sciences, Inc. - RXi Pharmaceuticals Corporation - Theravasc, Inc. - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/3t...g_pipeline
CUR: 0.32 (+0.01)
Huntington's Disease Pipeline Review, H2 2015
M2 - Thu Jan 21, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/kbmbtc/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Huntington's Disease Overview - Therapeutics Development - Pipeline Products for Huntington's Disease - Overview - Pipeline Products for Huntington's Disease - Comparative Analysis - Huntington's Disease - Therapeutics under Development by Companies - Huntington's Disease - Therapeutics under Investigation by Universities/Institutes - Huntington's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Huntington's Disease - Products under Development by Companies - Huntington's Disease - Products under Investigation by Universities/Institutes - Huntington's Disease - Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - AFFiRiS AG - Alnylam Pharmaceuticals, Inc. - Angita B.V. - Astellas Pharma Inc. - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - BioMarin Pharmaceutical Inc. - BrainStorm Cell Therapeutics Inc. - Chong Kun Dang Pharmaceutical Corp. - Kadmon Corporation, LLC - KineMed, Inc. - Living Cell Technologies Limited - Medesis Pharma S.A. - Neuralstem, Inc. - Neurimmune Holding AG - NeuroNascent, Inc. - New World Laboratories, Inc. - nLife Therapeutics, S.L. - NsGene A/S - Provid Pharmaceuticals, Inc. - QR Pharma, Inc. - Raptor Pharmaceuticals Inc - reMYND NV - RestorGenex Corporation - Rhenovia Pharma Limited - Sangamo BioSciences, Inc. - Vaccinex, Inc. - Vertex Pharmaceuticals Incorporated - VistaGen Therapeutics , Inc. - VivaCell Biotechnology Espana S.L. - Voyager Therapeutics, Inc. - Vybion, Inc. - Zenobia Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/kb...untingtons
VRTX: 90.63 (-1.49), BMRN: 97.40 (-0.05), VYGR: 13.85 (-0.04), RPTP: 9.00 (+0.03), KNMD: (), SGMO: 5.00 (+0.18), BCLI: 2.44 (+0.01), CUR: 0.32 (+0.01)
3 Stocks Tackling Concussion Issues in Pro Athletes
ACCESSWIRE - Wed Jan 20, 7:45AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 20, 2016 / The 2015 drama Concussion starring Will Smith follows the story of Dr. Bennet Omalu's battle with the National Football League to acknowledge research on the brain damage suffered by professional football players. After examining the brains of many deceased NFL players, Dr. Omalu coined the term chronic traumatic encephalopathy (CTE) to represent the large accumulation of tau protein on the brain causing a wide range of mental problems.
STEM: 1.43 (+0.03), CEMI: 7.06 (-0.05), CUR: 0.32 (+0.01)
Neuralstem's Preclinical Alzheimer's Disease Data Published In Stem Cells Translational Medicine
PR Newswire - Mon Jan 11, 6:32AM CST
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced publication of "Human Cortical Neural Stem Cells Expressing Insulin-Like Growth Factor-1: A Novel Cellular Therapy for Alzheimer's Disease," in Stem Cells Translational Medicine (http://stemcellstm.alphamedpress.org/content/early/2016/01/07/sctm.2015-0103.short?rss=1).
CUR: 0.32 (+0.01)
Neuralstem to Present at the Biotech Showcase 2016 Conference in San Francisco
PR Newswire - Wed Jan 06, 7:35AM CST
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that it will present at the Biotech Showcase 2016 on Tuesday, January 12, 2016. The presentation is scheduled at 2:00PM PST, in the Parc 55 Hilton Hotel, San Francisco.
CUR: 0.32 (+0.01)
BUYINS.NET: ITB, GTLS, GJV, ISF, CUR, PWZ Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Dec 23, 6:55AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of iShares Dow Jones US Home Construction Index Fund (NYSE:ITB), Chart Industries Inc (NASDAQ:GTLS), Synthetic FixedIncome Securities Inc. 7.00% Fixed Rate Structured Repackaged A (NYSE:GJV), ING GROEP N.V. 6.375% ING Perpetual Hybrid Capital Securities (NYSE:ISF), Diagnocure Inc (NASDAQ:CUR), Powershares Exchange-Traded Fund Trust II (NYSE
WZ) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ISF: 25.91 (+0.03), IND: 24.99 (unch), ITB: 27.62 (-0.11), GJV: 26.05 (+0.06), PWZ: 26.59 (-0.02), GTLS: 31.05 (-1.22), EQAL: 26.09 (-0.17), CUR: 0.32 (+0.01)
Major Depressive Disorder - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/496zq2/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Major Depressive Disorder's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Major Depressive Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aequus Pharmaceuticals Inc. - Alkermes Plc - Allergan Plc - Angelini Group - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - e-Therapeutics Plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - H. Lundbeck A/S - Hua Medicine Ltd. - Intra-Cellular Therapies, Inc. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Johnson & Johnson - Lead Discovery Center GmbH - Luye Pharma Group Ltd. - Mapreg S.A.S. - Methylation Sciences Inc. - miCure Therapeutics Ltd. - Mitsubishi Tanabe Pharma Corporation - Naurex, Inc. - Neuralstem, Inc. - nLife Therapeutics, S.L. - Otsuka Holdings Co., Ltd. - Pherin Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Richter Gedeon Nyrt. - Saniona AB - Sumitomo Dainippon Pharma Co., Ltd. - Sunovion Pharmaceuticals Inc. - Suven Life Sciences Ltd. - VistaGen Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/49...depressive
LLY: 81.16 (-0.13), BMY: 56.48 (+0.06), GSK: 43.42 (-0.16), ALKS: 49.58 (-1.42), AGN: 243.94 (+0.51), JNJ: 118.81 (-0.65), ITCI: 42.40 (+1.53), CUR: 0.32 (+0.01)
Neuralstem Achieves 50% Enrollment in NSI-189 Phase 2 Trial in Major Depressive Disorder
GlobeNewswire - Wed Sep 21, 7:32AM CDT
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced that it has reached over 50% enrollment in its Phase 2 clinical trial evaluating NSI-189, a novel neurogenic small molecule, for the treatment of major depressive disorder (MDD).
CUR: 0.32 (+0.01)
Neuralstem Presented NSI-189 Preclinical Data in Type 1 and Type 2 Diabetes at the Annual Meeting of the Diabetic Neuropathy Study Group
GlobeNewswire - Mon Sep 12, 7:32AM CDT
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell proprietary technology, announced that Karl Johe, Ph.D., Chief Scientific Officer, presented the poster, "Therapeutic Efficacy of NSI-189 in Diabetic Mice," at the Annual Meeting of the Diabetic Neuropathy Study Group of the EASD (European Association for the Study of Diabetes), held in Bucharest, Romania, on September 11. The data demonstrate the potential for NSI-189 to reverse neuropathies resulting from diabetes in two well-recognized animal models.
CUR: 0.32 (+0.01)
Neuralstem Receives $20,000,000 Strategic Investment from Tianjin Pharmaceutical Group
GlobeNewswire - Mon Sep 12, 7:03AM CDT
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced that on September 7, 2016, it entered into definitive agreements with Tianjin Pharmaceutical Holding Group for the private placement of common stock and convertible preferred stock for gross proceeds of $20,000,000. Neuralstem intends to use the net proceeds from the offering for clinical research and development and general corporate purposes.
CUR: 0.32 (+0.01)
Neuralstem Reports Second Quarter 2016 Results and Provides Business and Clinical Updates
GlobeNewswire - Thu Aug 11, 3:05PM CDT
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, reported its financial results and provided business and clinical updates for the three and six months periods ended June 30, 2016.
CUR: 0.32 (+0.01)
Neuralstem Announces New Chairman and Further Reorganization Plans
GlobeNewswire - Mon Jun 13, 7:45AM CDT
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced, in furtherance of its reorganization plans and focus on clinical development, that Richard Daly, the company's president and chief executive officer, has been appointed chairman of the board of directors. Mr. Daly's appointment as chairman will allow Dr. Karl Johe, the company's founder, chief scientific officer and former chairman, to focus exclusively on the development of the company's product candidates.
CUR: 0.32 (+0.01)
Neuralstem Announces Plan of Reorganization to Further Align Business with Strategic Intent
PR Newswire - Fri May 20, 7:32AM CDT
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced a corporate reorganization to further align the company's resources on advancing the NSI-189 neurogenic small molecule program, currently in a Phase 2 clinical trial for the treatment of major depressive disorder, and to continue to pursue collaborations for the NSI-566 stem cell therapy program that will expedite clinical development.
CUR: 0.32 (+0.01)
Neuralstem to Raise $1.08 Million
PR Newswire - Thu May 12, 3:54PM CDT
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced that it has entered into a definitive agreement to sell 2,700,000 shares of its common stock and warrants to purchase 2,700,000 shares of common stock in a private placement. The securities are being sold in a private offering at a price of $0.40 per one share of common stock and one common stock purchase warrant. The warrants have an exercise price of $0.40 per share, are immediately exercisable and expire on the fifth anniversary of the date of issuance. The shares of common stock and warrants are immediately separable and will be issued separately.
CUR: 0.32 (+0.01)
Neuralstem Announces First Patient Enrolled in Phase 2 Clinical Trial in Major Depressive Disorder
PR Newswire - Thu May 12, 8:07AM CDT
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced that the first patient has been enrolled in the double-blind, placebo-controlled multi-center Phase 2 study of NSI-189 for the treatment of major depressive disorder (MDD).
CUR: 0.32 (+0.01)
Neuralstem Reports Fiscal First Quarter 2016 Results and Business Update
PR Newswire - Mon May 09, 7:05AM CDT
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, reported its financial results for the three months ended March 31, 2016 and provided a business update.
CUR: 0.32 (+0.01)
Neuralstem Prices Underwritten Public Offering of Securities
PR Newswire - Tue May 03, 7:22AM CDT
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $0.40 per share and warrants to purchase 20,000,000 shares of common stock. The warrants have an exercise price of $0.40 per share, are immediately exercisable and expire on the fifth anniversary of the date of issuance. The shares of common stock and warrants are immediately separable and will be issued separately.
CUR: 0.32 (+0.01)
Neuralstem Announces Proposed Public Offering of Securities
PR Newswire - Mon May 02, 3:01PM CDT
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The shares of common stock and warrants will be immediately separable and will be issued separately. All securities in the offering are being offered by Neuralstem. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Roth Capital Partners is acting as sole book runner and Brean Capital is acting as co-manager in the offering.
CUR: 0.32 (+0.01)
Diabetic Neuropathy Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/hz8k3l/diabetic) has announced the addition of the "Diabetic Neuropathy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Diabetic Neuropathy Overview - Therapeutics Development - Pipeline Products for Diabetic Neuropathy - Overview - Pipeline Products for Diabetic Neuropathy - Comparative Analysis - Diabetic Neuropathy - Therapeutics under Development by Companies - Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes - Diabetic Neuropathy - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Diabetic Neuropathy - Products under Development by Companies - Diabetic Neuropathy - Products under Investigation by Universities/Institutes - Diabetic Neuropathy - Companies Involved in Therapeutics Development - Araim Pharmaceuticals Inc. - Bristol-Myers Squibb Company - Cebix Incorporated - Celgene Corporation - Glucox Biotech AB - Longevity Biotech, Inc - Lpath, Inc. - Neuralstem, Inc. - NovaLead Pharma Pvt. Ltd. - Nuvo Research Inc. - Omeros Corporation - Pfizer Inc. - R-Tech Ueno, Ltd. - Reata Pharmaceuticals, Inc. - Relief Therapeutics S.A. - Sumitomo Dainippon Pharma Co., Ltd. - Virobay Inc. - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/hz8k3l/diabetic
PFE: 34.26 (+0.11), VBAY: (), BMY: 56.48 (+0.06), LPTN: 3.89 (+0.29), OMER: 11.64 (-0.26), CUR: 0.32 (+0.01), CELGZ: 1.24 (+0.04)
Neuralstem Presented Cell Therapy Update At Phacilitate Cell & Gene Therapy World Conference
PR Newswire - Wed Jan 27, 8:02AM CST
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company using neural stem cell technology to develop regenerative therapies and small molecule pharmaceutical drugs for CNS diseases and disorders, announced that Karl Johe, Ph.D., Neuralstem's Chairman and Chief Scientific Officer, provided an update on the company's ongoing NSI-566 cell therapy clinical programs at the Phacilitate Cell & Gene Therapy World conference in Washington D.C.
CUR: 0.32 (+0.01)
Global Ageing Development Pipeline Review, H2 2015
M2 - Wed Jan 27, 4:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/3tlrh3/ageing_pipeline) has announced the addition of the "Ageing - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ageing, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ageing and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Ageing Overview - Therapeutics Development - Pipeline Products for Ageing - Overview - Pipeline Products for Ageing - Comparative Analysis - Ageing - Therapeutics under Development by Companies - Ageing - Therapeutics under Investigation by Universities/Institutes - Ageing - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Ageing - Products under Development by Companies - Ageing - Products under Investigation by Universities/Institutes - Ageing - Companies Involved in Therapeutics Development - Bioo Therapeutics - Mapreg S.A.S. - Neuralstem, Inc. - RepliCel Life Sciences, Inc. - RXi Pharmaceuticals Corporation - Theravasc, Inc. - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/3t...g_pipeline
CUR: 0.32 (+0.01)
Huntington's Disease Pipeline Review, H2 2015
M2 - Thu Jan 21, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/kbmbtc/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Huntington's Disease Overview - Therapeutics Development - Pipeline Products for Huntington's Disease - Overview - Pipeline Products for Huntington's Disease - Comparative Analysis - Huntington's Disease - Therapeutics under Development by Companies - Huntington's Disease - Therapeutics under Investigation by Universities/Institutes - Huntington's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Huntington's Disease - Products under Development by Companies - Huntington's Disease - Products under Investigation by Universities/Institutes - Huntington's Disease - Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - AFFiRiS AG - Alnylam Pharmaceuticals, Inc. - Angita B.V. - Astellas Pharma Inc. - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - BioMarin Pharmaceutical Inc. - BrainStorm Cell Therapeutics Inc. - Chong Kun Dang Pharmaceutical Corp. - Kadmon Corporation, LLC - KineMed, Inc. - Living Cell Technologies Limited - Medesis Pharma S.A. - Neuralstem, Inc. - Neurimmune Holding AG - NeuroNascent, Inc. - New World Laboratories, Inc. - nLife Therapeutics, S.L. - NsGene A/S - Provid Pharmaceuticals, Inc. - QR Pharma, Inc. - Raptor Pharmaceuticals Inc - reMYND NV - RestorGenex Corporation - Rhenovia Pharma Limited - Sangamo BioSciences, Inc. - Vaccinex, Inc. - Vertex Pharmaceuticals Incorporated - VistaGen Therapeutics , Inc. - VivaCell Biotechnology Espana S.L. - Voyager Therapeutics, Inc. - Vybion, Inc. - Zenobia Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/kb...untingtons
VRTX: 90.63 (-1.49), BMRN: 97.40 (-0.05), VYGR: 13.85 (-0.04), RPTP: 9.00 (+0.03), KNMD: (), SGMO: 5.00 (+0.18), BCLI: 2.44 (+0.01), CUR: 0.32 (+0.01)
3 Stocks Tackling Concussion Issues in Pro Athletes
ACCESSWIRE - Wed Jan 20, 7:45AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 20, 2016 / The 2015 drama Concussion starring Will Smith follows the story of Dr. Bennet Omalu's battle with the National Football League to acknowledge research on the brain damage suffered by professional football players. After examining the brains of many deceased NFL players, Dr. Omalu coined the term chronic traumatic encephalopathy (CTE) to represent the large accumulation of tau protein on the brain causing a wide range of mental problems.
STEM: 1.43 (+0.03), CEMI: 7.06 (-0.05), CUR: 0.32 (+0.01)
Neuralstem's Preclinical Alzheimer's Disease Data Published In Stem Cells Translational Medicine
PR Newswire - Mon Jan 11, 6:32AM CST
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced publication of "Human Cortical Neural Stem Cells Expressing Insulin-Like Growth Factor-1: A Novel Cellular Therapy for Alzheimer's Disease," in Stem Cells Translational Medicine (http://stemcellstm.alphamedpress.org/content/early/2016/01/07/sctm.2015-0103.short?rss=1).
CUR: 0.32 (+0.01)
Neuralstem to Present at the Biotech Showcase 2016 Conference in San Francisco
PR Newswire - Wed Jan 06, 7:35AM CST
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that it will present at the Biotech Showcase 2016 on Tuesday, January 12, 2016. The presentation is scheduled at 2:00PM PST, in the Parc 55 Hilton Hotel, San Francisco.
CUR: 0.32 (+0.01)
BUYINS.NET: ITB, GTLS, GJV, ISF, CUR, PWZ Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Dec 23, 6:55AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of iShares Dow Jones US Home Construction Index Fund (NYSE:ITB), Chart Industries Inc (NASDAQ:GTLS), Synthetic FixedIncome Securities Inc. 7.00% Fixed Rate Structured Repackaged A (NYSE:GJV), ING GROEP N.V. 6.375% ING Perpetual Hybrid Capital Securities (NYSE:ISF), Diagnocure Inc (NASDAQ:CUR), Powershares Exchange-Traded Fund Trust II (NYSE
WZ) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: ISF: 25.91 (+0.03), IND: 24.99 (unch), ITB: 27.62 (-0.11), GJV: 26.05 (+0.06), PWZ: 26.59 (-0.02), GTLS: 31.05 (-1.22), EQAL: 26.09 (-0.17), CUR: 0.32 (+0.01)
Major Depressive Disorder - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/496zq2/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Major Depressive Disorder's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Major Depressive Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aequus Pharmaceuticals Inc. - Alkermes Plc - Allergan Plc - Angelini Group - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - e-Therapeutics Plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - H. Lundbeck A/S - Hua Medicine Ltd. - Intra-Cellular Therapies, Inc. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Johnson & Johnson - Lead Discovery Center GmbH - Luye Pharma Group Ltd. - Mapreg S.A.S. - Methylation Sciences Inc. - miCure Therapeutics Ltd. - Mitsubishi Tanabe Pharma Corporation - Naurex, Inc. - Neuralstem, Inc. - nLife Therapeutics, S.L. - Otsuka Holdings Co., Ltd. - Pherin Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Richter Gedeon Nyrt. - Saniona AB - Sumitomo Dainippon Pharma Co., Ltd. - Sunovion Pharmaceuticals Inc. - Suven Life Sciences Ltd. - VistaGen Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/49...depressive
LLY: 81.16 (-0.13), BMY: 56.48 (+0.06), GSK: 43.42 (-0.16), ALKS: 49.58 (-1.42), AGN: 243.94 (+0.51), JNJ: 118.81 (-0.65), ITCI: 42.40 (+1.53), CUR: 0.32 (+0.01)
(0)
(0)Scroll down for more posts ▼